• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • About
  • Our Products
    • Restoret
  • Team
EyeBio

EyeBio

  • Business Development
  • News
  • Contact

Back to Team

Keith Baker

Vice President of Clinical Development

LinkedIn

Keith joined EyeBio as Vice President of Clinical Development in 2023. He is responsible in this capacity for the strategy and execution of EyeBio’s clinical research programs across its portfolio.

As a comprehensive ophthalmologist, Keith has over 20 years of clinical and industry experience in ophthalmology. Most recently, Keith served as Executive Medical Director at Gyroscope Therapeutics, where he led Medical Affairs for the GT005 development program in Geographic Atrophy. Prior to Gyroscope, Keith served in multiple positions of increasing responsibility at Regeneron Pharmaceuticals, beginning with the successful launch of EYLEA in 2012.

Keith is a graduate of Duke University, Dartmouth (Geisel) Medical School, and the Amos Tuck School of Business at Dartmouth College. He completed his ophthalmology residency training at the University of North Carolina Hospitals in Chapel Hill, NC, where he also served as Chief Resident.

Footer

Contact Us

Please fill out the brief form below with any questions or inquiries, and a member of our team will connect with you soon.

Business Development

EyeBio is bringing disruptive innovation to the field of ophthalmology. We actively seek to expand our pipeline of promising investigational therapies, and we welcome inquiries regarding in-licensing and acquisition of assets into our portfolio.

To learn more, please contact Sarah Milsom, Chief Operating Officer of EyeBio, at s.milsom@nulleyebiotech.com.

Privacy Policy
Terms of Use
Cookie Policy
Accessibility Statement

EyeBio

LinkedIn

Copyright © 2022 EyeBio

logo
  • About
  • Our Products
    • Restoret
  • Team
  • Business Development
  • News
  • Contact